espanolEl cancer de prostata es el primer cancer en numero de casos en varones y el segundo mas mortal. La edad supone el principal factor de riesgo para su desarrollo, siendo al diagnostico en torno a 66 anos. El pronostico del cancer de prostata depende del estadio en el momento del diagnostico, presentando enfermedad localizada hasta en un 80% de los casos. Sin embargo, hasta un 20%-30% de los pacientes presentaran una recidiva de la enfermedad. Los factores determinantes para la estadificacion y la estratificacion del riesgo son la extension de la enfermedad, la gradacion de Gleason y los niveles de PSA. Los tumores confinados a la glandula se tratan con tecnicas radicales, tanto quirurgicas como radioterapicas, y requieren un abordaje multidisciplinar. El tratamiento en estadios avanzados se basa en la castracion androgenica acompanada de inhibidores de la senalizacion del receptor androgenico como abiraterona y enzalutamida, del uso de quimioterapia basada en docetaxel y cabazitaxel y del empleo de radium-223. EnglishProstate cancer is the leading malignancy in men and the second most deadly. Age is the main risk factor for the development of the disease, with an average age at diagnosis of 66 years and an increase in incidence from the age of 55. The prognosis of prostate cancer depends on the stage at diagnosis, with localised disease occurring in up to 80% of cases. However, up to 20%-30% of patients will have recurrent disease. The determining factors for staging and risk stratification in prostate cancer are the extent of disease, Gleason grade and PSA levels. PSA level is also the main screening tool. Tumours confined to the prostate gland are usually treated by radical surgical and radiotherapy-based techniques, always requiring a multidisciplinary approach. Treatment in advanced stages is based in androgen deprivation therapies with androgen-receptor signalling inhibitors abiraterone and enzalutamide, as well as treatment with docetaxel, cabazitaxel and radium-223.